BiotechTube
Home/Pipeline/Endometriosis Discovery Program

Endometriosis Discovery Program

Endometriosis

DiscoveryActive

Key Facts

Indication
Endometriosis
Phase
Discovery
Status
Active
Company
Metri Bio

About Metri Bio

Metri Bio is an early-stage biotech developing novel therapeutics for endometriosis and other endometrial diseases, addressing a massive unmet need in women's health. Founded in 2021, the company emerged from stealth in 2024 with a $5M pre-seed round and is built on a proprietary 3D endometrial modeling technology from the Sozen Lab at Yale. Led by a team with deep scientific and translational expertise, Metri Bio aims to move beyond symptomatic relief to discover and develop disease-modifying treatments. The company is currently expanding its team and R&D operations to advance its discovery platform and therapeutic programs toward preclinical studies.

View full company profile

Therapeutic Areas

EndometriosisWomen's HealthReproductive Health

Other Endometriosis Drugs

DrugCompanyPhase
Promarker™EndoProteomics InternationalLate‑stage validation
EV‑EndoCarthericsPreclinical
Endometriosis ProgramCyclana BioDiscovery
Endometriosis Genetic StudyJuneau BiosciencesDiscovery
Potential Diagnostic DevelopmentJuneau BiosciencesResearch
Endometriosis Test SuiteHeranova LifesciencesPre-clinical
EndomTestKephera DiagnosticsCommercial (LDT)
ENDO-205EndoCyclic TherapeuticsPhase 1
Undisclosed ImmunotherapyApheon BiosciencePreclinical
FMCFimmCytePre-clinical
ABC-201AbcelyPreclinical
ERβ Modulator ProgramCadenza BioPreclinical